Clinically, CARMA3 is significantly upregulated in HCC tissues and strongly associated with advanced tumor stage and poor patient prognosis, as confirmed by analyses of Oncomine and TCGA datasets. This evidence concerns the gene CARD10 and hepatocellular carcinoma.